You are here:
NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Technology appraisal guidance
Reference number:
TA193
Published:
28 July 2010
Guidance
Tools and resources
Information for the public
History
Research recommendations coming out of this guidance
There are no research recommendations for TA193